Circadian rhythm dysfunction represents one of the earliest and most prevalent non-cognitive manifestations of Alzheimer's disease (AD), often appearing years before the onset of overt memory impairment. The circadian system, governed by the suprachiasmatic nucleus of the hypothalamus, orchestrates approximately 24-hour cycles in physiological, behavioral, and cognitive processes essential for maintaining homeostasis[@saper2010][Saper CB 2010, Sleep state switching](https://pubmed.ncbi.nlm.nih.gov/21145406/). In Alzheimer's disease, this precisely regulated system becomes profoundly disrupted, contributing to the characteristic sleep-wake cycle disturbances, Sundowning syndrome, and accelerated cognitive decline observed in affected individuals.
Circadian rhythm dysfunction represents one of the earliest and most prevalent non-cognitive manifestations of Alzheimer's disease (AD), often appearing years before the onset of overt memory impairment. The circadian system, governed by the suprachiasmatic nucleus of the hypothalamus, orchestrates approximately 24-hour cycles in physiological, behavioral, and cognitive processes essential for maintaining homeostasis[@saper2010][Saper CB 2010, Sleep state switching](https://pubmed.ncbi.nlm.nih.gov/21145406/). In Alzheimer's disease, this precisely regulated system becomes profoundly disrupted, contributing to the characteristic sleep-wake cycle disturbances, Sundowning syndrome, and accelerated cognitive decline observed in affected individuals.
The relationship between circadian dysfunction and Alzheimer's disease is bidirectional and synergistic. On one hand, the neurodegenerative processes inherent to Alzheimer's disease directly impair the circadian system through pathology affecting the suprachiasmatic nucleus and its efferent projections. On the other hand, circadian disruption itself may accelerate Alzheimer's disease pathogenesis through effects on amyloid-β metabolism, tau phosphorylation, neuroinflammation, and hippocampal synaptic plasticity[@musiek2014][Musiek ES 2014, Circadian rhythms and sleep: implications for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25490020/). This reciprocal relationship creates a vicious cycle wherein each domain exacerbates the other, ultimately accelerating disease progression.
At the cellular level, the circadian clock operates through a sophisticated transcriptional-translational feedback loop involving a suite of core clock genes and proteins[@reppert2001][Reppert SM 2001, Molecular analysis of mammalian circadian rhythms](https://pubmed.ncbi.nlm.nih.gov/11283313/). The positive limb of this oscillator comprises the transcription factors CLOCK (Circadian Locomotor Output Cycles Kaput) and BMAL1 (Brain and Muscle ARNT-Like 1), which heterodimerize to form the CLOCK-BMAL1 complex. This complex binds to E-box enhancer elements in the promoters of target genes, driving the expression of period genes (PER1, PER2, PER3) and cryptochrome genes (CRY1, CRY2)[Dunlap JC 1999, Molecular bases for circadian clocks](https://pubmed.ncbi.nlm.nih.gov/10225437/).
The negative feedback limb consists of the PER and CRY proteins, which accumulate in the cytoplasm, form PER-CRY complexes, and translocate back to the nucleus to inhibit their own transcription by interfering with CLOCK-BMAL1 activity[Kume K 1999, mCRY1 and mCRY2 are essential components of the negative limb of the circadia...](https://pubmed.ncbi.nlm.nih.gov/10204645/). This creates an approximately 24-hour oscillation in clock gene expression that persists even in isolated cellular systems, demonstrating its cell-autonomous nature.
Additional accessory oscillators include nuclear receptors such as REV-ERBα and RORα, which regulate BMAL1 expression through competing binding to ROR response elements, adding further complexity and robustness to the circadian system[Preitner N 2002, The orphan nuclear receptor REV-ERBα controls circadian transcription through...](https://pubmed.ncbi.nlm.nih.gov/12150932/). The PAR-bZIP transcription factors (DBP, TEF, HLF) add yet another layer of regulation, driving the expression of genes involved in detoxification, metabolism, and cellular stress responses[Gachon F 2006, The PAR bZIP transcription factor DBP and the histone acetyltransferase PCAF ...](https://pubmed.ncbi.nlm.nih.gov/17036042/).
The suprachiasmatic nucleus, a small bilateral structure composed of approximately 20,000 neurons in the anterior hypothalamus, serves as the master circadian pacemaker in mammals[Moore RY 1972, A retinohypothalamic projection in the rat](https://pubmed.ncbi.nlm.nih.gov/4641970/). The suprachiasmatic nucleus receives direct photic input from intrinsically photosensitive retinal ganglion cells containing melanopsin, which transduce environmental light information to the suprachiasmatic nucleus via the retinohypothalamic tract[Berson DM 2002, Phototransduction by retinal ganglion cells that set the circadian clock](https://pubmed.ncbi.nlm.nih.gov/11816488/). This photic input synchronizes the suprachiasmatic nucleus's intrinsic rhythm to the external light-dark cycle, ensuring appropriate alignment of internal biological rhythms with external environmental cues.
The suprachiasmatic nucleus is not a homogeneous structure but rather comprises distinct functional subregions. The ventrolateral "core" receives direct retinal input and contains vasoactive intestinal peptide (VIP)-expressing neurons that communicate timing signals to the dorsomedial "shell" region[Abrahamson EE 2001, Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organiza...](https://pubmed.ncbi.nlm.nih.gov/11516111/). The shell contains arginine vasopressin (AVP)-expressing neurons that generate autonomous circadian rhythms and project to downstream nuclei controlling sleep, arousal, body temperature, and hormone secretion.
Critically, the suprachiasmatic nucleus does not act as a solitary oscillator but rather as a population of coupled cellular oscillators. Individual suprachiasmatic nucleus neurons exhibit heterogeneous phase relationships, creating a robust system that maintains stable periodicity despite cellular-level variability[Liu AC 2007, Intercellular coupling confers robustness against mutations in the suprachias...](https://pubmed.ncbi.nlm.nih.gov/17498036/). This coupling is mediated through gap junctions and neuropeptide signaling, ensuring coherent output to downstream target structures.
Sleep architecture becomes profoundly disrupted in Alzheimer's disease, with alterations evident even in pre-symptomatic individuals carrying pathogenic mutations[Backhaus W 2023, Sleep alterations in familial Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36734123/). Polysomnographic studies reveal reduced sleep efficiency, increased nighttime awakenings, decreased REM sleep duration, and fragmentation of both REM and non-REM sleep stages[Bliwise DL 2004, Sleep disorders in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/15063309/). These disturbances correlate with disease severity and predict more rapid cognitive decline.
The characteristic "sundowning" phenomenon, wherein behavioral symptoms worsen in the late afternoon and evening hours, affects up to 66% of Alzheimer's disease patients and represents a quintessential manifestation of circadian dysfunction[Bachman D 2006, Sundowning and other temporally related agitation in dementia](https://pubmed.ncbi.nlm.nih.gov/16460377/). Sundowning manifests as increased agitation, confusion, hallucinations, and motor activity during the evening, often leading to caregiver stress and institutionalization.
Advanced Alzheimer's disease patients frequently exhibit a complete reversal of the normal sleep-wake pattern, with nighttime wakefulness and daytime somnolence predominating[Moe KE 1991, Sleep, aging, and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1789913/). This inversion reflects the loss of circadian organization and may contribute to the weight loss, immune dysfunction, and increased fall risk observed in affected individuals.
The circadian rhythm of core body temperature, normally characterized by a nadir in the early morning and peak in the late afternoon, becomes blunted and phase-advanced in Alzheimer's disease patients[van Someren EJ 1996, Circadian rest-activity rhythm disturbances in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/8828786/). This flattened amplitude may reflect reduced suprachiasmatic nucleus output and impaired thermoregulatory capacity. The dampened temperature rhythm has functional consequences, as temperature rhythms serve as potent zeitgebers for peripheral circadian oscillators in tissues throughout the body.
Melatonin secretion, the hormone primarily responsible for mediating the effects of light on circadian timing and promoting sleep, becomes dramatically altered in Alzheimer's disease[Wu YH 2005, The human pineal gland and melatonin in aging and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/15683543/). Nocturnal melatonin levels decline with advancing age, but this decline is accelerated in Alzheimer's disease, with some studies reporting near-complete absence of the melatonin circadian rhythm in advanced disease. This melatonin deficiency likely contributes to sleep disturbances and may have pathogenic implications, as melatonin possesses antioxidant, anti-amyloid, and neuroprotective properties.
Cortisol, the primary effector of the hypothalamic-pituitary-adrenal axis, normally exhibits a robust circadian rhythm with peak levels in the early morning and nadir around midnight. In Alzheimer's disease, this rhythm becomes dysregulated, with elevated evening cortisol levels and flattened amplitude[Swaab DF 1985, The suprachiasmatic nucleus of the human brain in relation to sex, age and se...](https://pubmed.ncbi.nlm.nih.gov/2860873/). Hypercortisolemia may accelerate neurodegeneration through glucocorticoid receptor-mediated effects on hippocampal neurons, creating another potential pathogenic pathway linking circadian dysfunction to disease progression.
Actigraphy studies reveal profound disruption of rest-activity rhythms in Alzheimer's disease, characterized by reduced amplitude, increased fragmentation, and phase advances in activity onset[Ancoli-Israel S 1997, Variations in circadian rhythms of activity, sleep, and light exposure relate...](https://pubmed.ncbi.nlm.nih.gov/9130332/). The robustness of activity rhythms, as measured by variables such as interdaily stability and intradaily variability, correlates with cognitive function and predicts institutionalization. These disruptions are evident even in mild cognitive impairment, suggesting that circadian dysfunction represents an early marker of neurodegeneration.
The loss of circadian organization in Alzheimer's disease extends to meal timing, with many patients exhibiting "grazing" behavior rather than discrete meals[Young KW 2001, Meal-time shifts and cognitive status in institutionalized elderly](https://pubmed.ncbi.nlm.nih.gov/11928235/). This disruption may contribute to metabolic dysfunction and weight loss, common problems in Alzheimer's disease patients.
Neuropathological studies reveal that the suprachiasmatic nucleus is vulnerable to Alzheimer's disease-related neurodegeneration, although the pattern of pathology differs somewhat from other brain regions[Zhou L 2022, Degeneration and mitochondrial dysfunction of suprachiasmatic nucleus in Alzh...](https://pubmed.ncbi.nlm.nih.gov/35758532/). While classic amyloid plaques and neurofibrillary tangles are relatively sparse in the suprachiasmatic nucleus compared to hippocampus and neocortex, the nucleus demonstrates selective vulnerability of VIP-expressing neurons, reduced neurons density, and evidence of oxidative stress.
The loss of VIP neurons in the suprachiasmatic nucleus core is particularly concerning, as these cells provide the coupling signal that synchronizes the entire circadian system[Kallo I 2004, VIP and AVP neurons in the suprachiasmatic nucleus of the mouse](https://pubmed.ncbi.nlm.nih.gov/15356290/). VIP deficiency may therefore create a "dissociated" suprachiasmatic nucleus, wherein individual neurons continue to oscillate but lose coherent output.
Astrocytic reactivity and microglial activation are evident in the suprachiasmatic nucleus of Alzheimer's disease patients, suggesting that neuroinflammation contributes to circadian dysfunction[Park J 2021, Neuroinflammation in the suprachiasmatic nucleus in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33771104/). The pro-inflammatory cytokine interleukin-1β, known to suppress clock gene expression, may mediate these effects.
Multiple studies demonstrate altered expression of core clock genes in Alzheimer's disease brain tissue and peripheral cells. In the hippocampus, a region critical for memory formation, BMAL1 and PER2 expression becomes dysregulated in a manner that correlates with cognitive impairment[Song H 2020, BMAL1 and PER2 expression in hippocampus of Alzheimer](https://pubmed.ncbi.nlm.nih.gov/31868580/).
Peripheral blood mononuclear cells from Alzheimer's disease patients show altered circadian rhythms of clock gene expression, suggesting that the circadian disturbance extends beyond the central nervous system[Chen Y 2019, Circadian clock genes in peripheral blood mononuclear cells of Alzheimer](https://pubmed.ncbi.nlm.nih.gov/30861483/).
The circadian transcription factor REV-ERBα, which regulates inflammatory gene expression, becomes downregulated in Alzheimer's disease brain[Dehgani-Saraein B 2023, Altered circadian clock gene expression in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37728782/). This reduction may contribute to the chronic neuroinflammation characteristic of the disease.
The relationship between circadian dysfunction and the hallmark proteinopathies of Alzheimer's disease is bidirectional. Amyloid-β, the peptide that aggregates into senile plaques, demonstrates circadian variation in its concentration, with higher levels during sleep and lower levels during wakefulness[Kang JE 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle](https://pubmed.ncbi.nlm.nih.gov/19779148/). This pattern reflects the fact that neuronal activity, which increases during wakefulness, promotes amyloid release, while sleep facilitates amyloid clearance through glymphatic pathway activation.
Conversely, amyloid pathology disrupts circadian function through multiple mechanisms. Amyloid deposition in the suprachiasmatic nucleus directly damages circadian neurons, while amyloid-induced oxidative stress and inflammation suppress clock gene expression[Roh JH 2012, Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid-β in mi...](https://pubmed.ncbi.nlm.nih.gov/23136432/).
Tau pathology also interacts with the circadian system. Hyperphosphorylated tau accumulates in the suprachiasmatic nucleus of Alzheimer's disease patients, potentially disrupting neuronal function[Zhou L 2023, Tau pathology in the suprachiasmatic nucleus in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36756674/).
Bright light exposure represents the most direct approach to enhancing circadian function in Alzheimer's disease. Light serves as the dominant zeitgeber for the circadian system, directly stimulating photoreceptors in the retina that project to the suprachiasmatic nucleus[Czeisler CA 1999, Stability, precision, and near-24-hour period of the human circadian pacemaker](https://pubmed.ncbi.nlm.nih.gov/10390589/). Appropriately timed bright light (typically morning exposure) can advance circadian phase, increase circadian amplitude, and improve sleep-wake consolidation.
Clinical trials of light therapy in Alzheimer's disease have yielded mixed results. While some studies demonstrate improved sleep efficiency, reduced nighttime awakenings, and enhanced cognitive function, others show minimal benefit[Forbes D 2014, Light therapy for improving cognition, activities of daily living, sleep, cha...](https://pubmed.ncbi.nlm.nih.gov/24569861/). The variable outcomes likely reflect differences in light intensity, timing, duration, and patient selection.
Given the dramatic reduction in endogenous melatonin in Alzheimer's disease, replacement therapy represents a logical intervention. Melatonin supplementation has demonstrated sleep-promoting effects in Alzheimer's disease patients, with improvements in sleep efficiency and reduced night-time awakenings[Cardinali DP 2002, The use of melatonin in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/12019380/). Additionally, melatonin's antioxidant and anti-amyloid properties may provide disease-modifying benefits beyond symptom management.
The timing of melatonin administration is critical, as exogenous melatonin shifts circadian phase in a time-dependent manner. Evening administration (typically 1-2 hours before desired sleep onset) optimally enhances circadian amplitude and improves sleep continuity.
Combination approaches using melatonin with light therapy may prove more effective than either intervention alone, as they address complementary aspects of circadian dysfunction[Hattori M 2015, Combined light and melatonin therapy for circadian rhythm sleep disorders in ...](https://pubmed.ncbi.nlm.nih.gov/25998214/).
Non-pharmacological behavioral interventions provide a complementary approach to enhancing circadian function. Consistent daily routines, including regular meal times, scheduled activities, and fixed sleep-wake schedules, help reinforce circadian rhythms through habituation[McCurry SM 2000, Increasing walking and bright light exposure to improve sleep in community-dw...](https://pubmed.ncbi.nlm.nih.gov/10894321/). Exposure to natural daylight, preferably in the morning, provides necessary zeitgeber input, while avoidance of bright light in the evening prevents inappropriate phase delays.
Physical activity represents a particularly potent zeitgeber, with exercise timing influencing circadian phase[Youngstedt SD 2005, Effects of exercise on sleep](https://pubmed.ncbi.nlm.nih.gov/15892924/).
Several pharmacological agents target circadian function or its consequences in Alzheimer's disease. Modafinil and armodafinil, wake-promoting agents, may help consolidate the sleep-wake cycle by increasing daytime alertness and reducing daytime napping[Kumar A 2017, Modafinil for daytime sleepiness in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/28183443/).
Orexin receptor antagonists such as suvorexant and lemborexant promote sleep by blocking orexin signaling, potentially improving sleep without the cognitive effects of traditional hypnotics[Herringa RJ 2021, Orexin receptor antagonists for the treatment of insomnia and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33464952/). These agents have demonstrated efficacy in Alzheimer's disease-related sleep disturbance.
Targeting the molecular clock itself represents a novel therapeutic approach. Small molecules that enhance BMAL1 expression or activity, stabilize PER proteins, or activate RORα may eventually allow direct manipulation of the circadian oscillator[Chen D 2022, Targeting circadian clock genes for drug discovery](https://pubmed.ncbi.nlm.nih.gov/34582564/).
The prominence of circadian dysfunction in Alzheimer's disease has prompted investigation of circadian measures as potential biomarkers. Actigraphy-derived rest-activity rhythm parameters predict cognitive decline and conversion from mild cognitive impairment to Alzheimer's disease[Lim AS 2013, Sleep fragmentation and the risk of incident Alzheimer](https://pubmed.ncbi.nlm.nih.gov/23814339/). Reduced circadian amplitude and increased fragmentation are associated with increased risk of incident dementia, suggesting that circadian disturbances may precede overt cognitive impairment.
CSF biomarkers of circadian function, including melatonin metabolites and clock gene expression in peripheral blood cells, may eventually provide minimally invasive markers of circadian health[Wu Y 2024, Melatonin metabolites as biomarkers for circadian function in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38263511/).
The presence of circadian dysfunction may also help differentiate Alzheimer's disease from other dementias. For instance, circadian disturbances may be more prominent in Lewy body dementia than in Alzheimer's disease, while the pattern of sleep disruption differs between frontotemporal dementia and Alzheimer's disease[Bodenstein F 2023, Sleep disorders in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/37002431/).
Research on circadian dysfunction in Alzheimer's disease continues to evolve, with several frontiers actively being explored. The role of the glymphatic system, which exhibits a circadian rhythm and is critical for amyloid clearance, represents a particularly promising area[Xie L 2013, Sleep drives metabolite clearance from the adult brain](https://pubmed.ncbi.nlm.nih.gov/24136970/).
The gut microbiome exhibits circadian rhythms that communicate with the central clock through various signaling pathways. The gut-brain axis may provide additional therapeutic targets for modulating circadian function, potentially through probiotics, prebiotics, or dietary interventions[Panda S 2021, The gut microbiota: a circadian clock synchronizer](https://pubmed.ncbi.nlm.nih.gov/34255173/).
Epigenetic mechanisms, including DNA methylation and histone modification, exhibit circadian patterns and may be altered in Alzheimer's disease[Masri S 2023, Plasticity of the circadian clock: from epigenetics to brain](https://pubmed.ncbi.nlm.nih.gov/37612291/). These changes could provide a mechanistic link between circadian dysfunction and the transcriptional dysregulation observed in Alzheimer's disease.
Circadian rhythm dysfunction in Alzheimer's disease represents a fundamental aspect of the disorder that extends beyond mere symptom management to encompass core disease mechanisms. The circadian system, comprising the master pacemaker in the suprachiasmatic nucleus and peripheral oscillators in virtually every tissue, becomes disrupted through multiple convergent pathways: direct suprachiasmatic nucleus pathology, clock gene dysregulation, amyloid and tau interactions, and neuroinflammation.
The clinical consequences of this dysfunction—sleep-wake cycle disturbances, Sundowning syndrome, body temperature dysregulation, and hormonal rhythm alterations—significantly impact quality of life for both patients and caregivers. Beyond symptomatic burden, circadian dysfunction may accelerate disease progression through effects on amyloid metabolism, tau pathology, and hippocampal function.
Therapeutic approaches targeting circadian function, including light therapy, melatonin supplementation, behavioral interventions, and pharmacological agents, offer meaningful benefits for patients. As understanding of the mechanistic links between circadian disruption and Alzheimer's disease pathogenesis deepens, more targeted interventions will likely emerge.
Related Analyses:
The following diagram shows the key molecular relationships involving Circadian Rhythm Dysfunction in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: